NASDAQ:ESTAEstablishment Labs Stock Price, Forecast & News

$20.76

+0.46 (+2.27 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$19.93

Now: $20.76▼

$20.90

50-Day Range

$14.00

MA: $17.30▼

$20.30

52-Week Range

$7.56

Now: $20.76▼

$29.78

Volume67,700 shs

Average Volume129,445 shs

Market Capitalization$484.31 million

P/E RatioN/A

Dividend YieldN/A

Beta1.47

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Establishment Labs has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.75, Establishment Labs has a potential upside of 28.9% from its current price of $20.76.
Amount of Analyst Coverage
Establishment Labs has only been the subject of 3 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Establishment Labs has received 83 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Establishment Labs has received 84 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Establishment Labs has received 50.30% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Establishment Labs and other stocks. Vote “Outperform” if you believe ESTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ESTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Establishment Labs does not currently pay a dividend.
Dividend Growth
Establishment Labs does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Establishment Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $171.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.64% of the stock of Establishment Labs is held by insiders.
Percentage Held by Institutions
53.33% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Establishment Labs are expected to grow in the coming year, from ($1.54) to ($1.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Establishment Labs is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Establishment Labs is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Establishment Labs has a P/B Ratio of 10.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.10 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ESTA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.establishmentlabs.com

Phone506 2434 2400

Debt

Debt-to-Equity Ratio0.54

Current Ratio6.58

Quick Ratio5.45

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$89.57 million

Price / Sales5.41

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.92 per share

Price / Book10.81

Profitability

EPS (Most Recent Fiscal Year)($1.86)

Net Income$-38,150,000.00

Net Margins-48.39%

Return on Equity-75.95%

Return on Assets-34.02%

Miscellaneous

Employees505

Outstanding Shares23,329,000

Market Cap$484.31 million

Next Earnings Date8/11/2020 (Estimated)

OptionableNot Optionable

Receive ESTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ESTA and its competitors with MarketBeat's FREE daily newsletter.

Establishment Labs (NASDAQ:ESTA) Frequently Asked Questions

How has Establishment Labs' stock been impacted by COVID-19 (Coronavirus)?

Establishment Labs' stock was trading at $15.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ESTA stock has increased by 37.0% and is now trading at $20.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Establishment Labs?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Establishment Labs.

When is Establishment Labs' next earnings date?

Establishment Labs is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Establishment Labs.

How were Establishment Labs' earnings last quarter?

Establishment Labs Holdings Inc (NASDAQ:ESTA) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.49. The firm had revenue of $24.48 million for the quarter, compared to analyst estimates of $23.10 million. Establishment Labs had a negative net margin of 48.39% and a negative return on equity of 75.95%. View Establishment Labs' earnings history.

What guidance has Establishment Labs issued on next quarter's earnings?

Establishment Labs updated its first quarter 2020 Pre-Market earnings guidance on Monday, March, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $23-25 million, compared to the consensus revenue estimate of $25.1 million.

What price target have analysts set for ESTA?

4 analysts have issued 1 year target prices for Establishment Labs' stock. Their forecasts range from $20.00 to $35.00. On average, they expect Establishment Labs' stock price to reach $26.75 in the next twelve months. This suggests a possible upside of 28.9% from the stock's current price. View analysts' price targets for Establishment Labs.

Has Establishment Labs been receiving favorable news coverage?

News stories about ESTA stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Establishment Labs earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutEstablishment Labs.

Who are some of Establishment Labs' key competitors?

Some companies that are related to Establishment Labs include Avanos Medical (AVNS), Inogen (INGN), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Rewalk Robotics (RWLK), Histogenics (HSGX), Precision Therapeutics (POAI), Ocugen (OCGN), Bionik Laboratories (BNKL) and NanoVibronix (NAOV). View all competitors.

What other stocks do shareholders of Establishment Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Establishment Labs investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Sientra (SIEN), Allergan (AGN), BCE (BCE), Canadian Imperial Bank of Commerce (CM), Conduent (CNDT), Canadian Natural Resources (CNQ), Chevron (CVX) and Evolus (EOLS).

Who are Establishment Labs' key executives?

Establishment Labs' management team includes the following people:

Mr. Juan Jose Chacon Quiros, Founder, CEO & Exec. Director (Age 47)
Mr. Salvador Santos Dada, Chief Operating Officer (Age 37)
Mr. Eddie De Oliveira, VP of Sales, Brazil (Age 36)
Ms. Renee M. Gaeta, Chief Financial Officer (Age 38)
Mr. Roberto De Mezerville, Chief Technology Officer (Age 39)

When did Establishment Labs IPO?

(ESTA) raised $50 million in an IPO on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen served as the underwriters for the IPO and BTIG was co-manager.

What is Establishment Labs' stock symbol?

Establishment Labs trades on the NASDAQ under the ticker symbol "ESTA."

Who are Establishment Labs' major shareholders?

Establishment Labs' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (3.95%), Perceptive Advisors LLC (3.95%), Cowen AND Company LLC (1.28%), Magnetar Financial LLC (0.88%), BigSur Wealth Management LLC (0.64%) and Morgan Stanley (0.59%). Company insiders that own Establishment Labs stock include David L Bonvenuto, Jw Asset Management, Llc, Mezerville Roberto De and Nicholas Sheridan Lewin. View institutional ownership trends for Establishment Labs.

Which major investors are selling Establishment Labs stock?

ESTA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Soleus Capital Management L.P., Two Sigma Investments LP, Victory Capital Management Inc., Victory Capital Management Inc., and BigSur Wealth Management LLC. View insider buying and selling activity for Establishment Labs.

Which major investors are buying Establishment Labs stock?

ESTA stock was bought by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, Prosight Management LP, Nuveen Asset Management LLC, Eagle Asset Management Inc., Magnetar Financial LLC, Kornitzer Capital Management Inc. KS, Jane Street Group LLC, and JPMorgan Chase & Co.. Company insiders that have bought Establishment Labs stock in the last two years include David L Bonvenuto, Jw Asset Management, Llc, Mezerville Roberto De, and Nicholas Sheridan Lewin. View insider buying and selling activity for Establishment Labs.

How do I buy shares of Establishment Labs?

Shares of ESTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Establishment Labs' stock price today?

One share of ESTA stock can currently be purchased for approximately $20.76.

How big of a company is Establishment Labs?

Establishment Labs has a market capitalization of $484.31 million and generates $89.57 million in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Establishment Labs employs 505 workers across the globe.

What is Establishment Labs' official website?

The official website for Establishment Labs is www.establishmentlabs.com.

How can I contact Establishment Labs?

Establishment Labs' mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The company can be reached via phone at 506 2434 2400 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff